Attention/vigilance in schizophrenia: Performance results from a large multi-site study of the Consortium on the Genetics of Schizophrenia (COGS)

Schizophrenia Research

Volumn 163, Issue 1-3, 2015, Pages 38-46

  Nuechterlein, Keith H ^a   Green, Michael F ^a,b   Calkins, Monica E ^c   Greenwood, Tiffany A ^d   Gur, Raquel E ^c   Gur, Ruben C ^c   Lazzeroni, Laura C ^e   Light, Gregory A ^d,f   Radant, Allen D ^g,h   Seidman, Larry J ^i,j   Siever, Larry J ^f,k   Silverman, Jeremy M ^f,k   Sprock, Joyce ^d,f   Stone, William S ^i,j   Sugar, Catherine A ^a,b,l   Swerdlow, Neal R ^d   Tsuang, Debby W ^g,h   Tsuang, Ming T ^d,m,n,o   Turetsky, Bruce I ^c   Braff, David L ^d,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e STANFORD UNIVERSITY   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

^h VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^k MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m University of California San Diego   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o HARVARD UNIVERSITY   (United States)

more..

Author keywords

Attention; Cognition; Continuous performance test; Endophenotype; Functional capacity; Genetics; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

ACADEMIC ACHIEVEMENT; ADULT; AGED; ALERTNESS; ARTICLE; CONTINUOUS PERFORMANCE TEST; CONTROLLED STUDY; DISEASE SEVERITY; EDUCATIONAL STATUS; ENDOPHENOTYPE; FEMALE; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL TASK; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; SCHIZOPHRENIA; SMOKING; VALIDATION PROCESS; ADOLESCENT; ATTENTION; CLINICAL TRIAL; COMPLICATION; GENETICS; MEMORY; MIDDLE AGED; MULTICENTER STUDY; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; PSYCHOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; ATTENTION; ENDOPHENOTYPES; FEMALE; HUMANS; MALE; MEMORY; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SMOKING; YOUNG ADULT;

EID: 84925844628     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2015.01.017     Document Type: Article

References (66)

1. Agnew-Blais J., Seidman L.J. Neurocognition in youth and young adults under age 30 at familial risk for schizophrenia: a quantitative and qualitative review. Cogn. Neuropsychiatr. 2013, 18(1-2):44-82.
2. Andreasen N.C. The Scale for the Assessment of Negative Symptoms (SANS) 1984, The University of Iowa, Iowa City, IA.
3. Andreasen N.C. The Scale for the Assessment of Positive Symptoms (SAPS) 1984, The University of Iowa, Iowa City, IA.
4. Andreasen N.C., Arndt S., Alliger R., Miller D., Flaum M. Symptoms of schizophrenia: methods, meanings, and mechanisms. Arch. Gen. Psychiatry 1995, 52(5):341-351.
5. Appels M.C., Sitskoorn M.M., Westers P., Lems E., Kahn R.S. Cognitive dysfunctions in parents of schizophrenic patients parallel the deficits found in patients. Schizophr. Res. 2003, 63(3):285-293.
6. Asarnow R.F., MacCrimmon D.J. Residual performance deficit in clinically remitted schizophrenics: a marker of schizophrenia?. J. Abnorm. Psychol. 1978, 87(6):597-608.
7. Asarnow R.F., Nuechterlein K.H., Subotnik K.L., Fogelson D.L., Torquato R., Payne D. Neurocognitive impairments in non-psychotic parents of children with schizophrenia and attention deficit hyperactivity disorder: the UCLA Family study. Arch. Gen. Psychiatry 2002, 59(11):1053-1060.
8. Barch D.M., Csernansky J.G., Conturo T., Snyder A.Z. Working and long-term memory deficits in schizophrenia: is there a common prefrontal mechanism?. J. Abnorm. Psychol. 2002, 111(3):478-494.
9. Braff D. Information processing and attention dysfunctions in schizophrenia. Schizophr. Bull. 1993, 19(2):233-259.
10. Chamberlain S.R., Odlaug B.L., Schreiber L.R., Grant J.E. Association between tobacco smoking and cognitive functioning in young adults. Am. J. Addict. 2012, 21(Suppl. 1):S14-S19.
11. Chen W.J. Taiwan Schizophrenia Linkage study: lessons learned from endophenotype-based genome-wide linkage scans and perspective. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2013, 162B(7):636-647.
12. Chen W.J., Liu S.K., Chang C.J., Lien Y.J., Chang Y.H., Hwu H.G. Sustained attention deficit and schizotypal personality features in nonpsychotic relatives of schizophrenic patients. Am. J. Psychiatry 1998, 155(9):1214-1220.
13. Chen W.J., Chang C.H., Liu S.K., Hwang T.J., Hwu H.G. Sustained attention deficits in nonpsychotic relatives of schizophrenic patients: a recurrence risk ratio analysis. Biol. Psychiatry 2004, 55(10):995-1000.
14. Cohen J. Statistical Power Analysis for the Behavioral Sciences 1988, Erlbaum, Hillsdale, NJ. second edition.
15. Cornblatt B.A., Keilp J.G. Impaired attention, genetics, and the pathophysiology of schizophrenia. Schizophr. Bull. 1994, 20(1):31-46.
16. Cornblatt B.A., Malhotra A.K. Impaired attention as an endophenotype for molecular genetic studies of schizophrenia. Am. J. Med. Genet. 2001, 105(1):11-15.
17. Cornblatt B.A., Risch N.J., Faris G., Friedman D., Erlenmeyer-Kimling L. The continuous performance test, identical pairs version (CPT-IP): I. New findings about sustained attention in normal families. Psychiatr. Res. 1988, 26(2):223-238.
18. Cornblatt B.A., Lenzenweger M.F., Erlenmeyer-Kimling L. The continuous performance test, identical pairs version: II. Contrasting attentional profiles in schizophrenic and depressed patients. Psychiatry Res. 1989, 29(1):65-85.
19. Donoghue K., Doody G.A. Effect of illegal substance use on cognitive function in individuals with a psychotic disorder: a review and meta-analysis. Neuropsychology 2012, 26(6):785-801.
20. Egan M.F., Goldberg T.E., Gscheidle T., Weirich M., Bigelow L.B., Weinberger D.R. Relative risk of attention deficits in siblings of patients with schizophrenia. Am. J. Psychiatry 2000, 157(8):1309-1316.
21. Finkelstein J.R.J., Cannon T.D., Gur R.E., Gur R.C., Moberg P.J. Attentional dysfunctions in neuroleptic-naive and neuroleptic-withdrawn schizophrenic patients and their siblings. J. Abnorm. Psychol. 1997, 106(2):203-212.
22. Franke P., Maier W., Hardt J., Hain C., Cornblatt B.A. Attentional abilities and measures of schizotypy: their variation and covariation in schizophrenic patients, their siblings, and normal control subjects. Psychiatry Res. 1994, 54(3):259-272.
23. Goodman S.H., Sewell D.R., Cooley E.L. Assessing levels of adaptive functioning: the role functioning scale. Community Ment. Health J. 1993, 29(2):119-131.
24. Gottesman I.I., Gould T.D. The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry 2003, 160(4):636-645.
25. Green D.M., Swets J.A. Signal Detection Theory and Psychophysics 1966, Wiley, New York.
26. Greenwood T.A., Braff D.L., Light G.A., Cadenhead K.S., Calkins M.E., Dobie D.J., Freedman R., Green M.F., Gur R.E., Gur R.C., Mintz J., Nuechterlein K.H., Olincy A., Radant A.D., Seidman L.J., Siever L.J., Silverman J.M., Stone W.S., Swerdlow N.R., Tsuang D.W., Tsuang M.T., Turetsky B.I., Schork N.J. Initial heritability analyses of endophenotypic measures for schizophrenia: the consortium on the genetics of schizophrenia. Arch. Gen. Psychiatry 2007, 64(11):1242-1250.
27. Greenwood T.A., Lazzeroni L.C., Murray S.S., Cadenhead K.S., Calkins M.E., Dobie D.J., Green M.F., Gur R.E., Gur R.C., Hardiman G., Kelsoe J.R., Leonard S., Light G.A., Nuechterlein K.H., Olincy A., Radant A.D., Schork N.J., Seidman L.J., Siever L.J., Silverman J.M., Stone W.S., Swerdlow N.R., Tsuang D.W., Tsuang M.T., Turetsky B.I., Freedman R., Braff D.L. Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am. J. Psychiatry 2011, 168(9):930-946.
28. Greenwood T.A., Swerdlow N.R., Gur R.E., Cadenhead K.S., Calkins M.E., Dobie D.J., Freedman R., Green M.F., Gur R.C., Lazzeroni L.C., Nuechterlein K.H., Olincy A., Radant A.D., Ray A., Schork N.J., Seidman L.J., Siever L.J., Silverman J.M., Stone W.S., Sugar C.A., Tsuang D.W., Tsuang M.T., Turetsky B.I., Light G.A., Braff D.L. Genome-wide linkage analyses of 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am. J. Psychiatry 2013, 170(5):521-532.
29. Grove W.M., Lebow B.S., Clementz B.A., Cerri A., Medus C., Iacono W.G. Familial prevalence and coaggregation of schizotypy indicators: a multitrait family study. J. Abnorm. Psychol. 1991, 100(2):115-121.
30. Gur R.E., Calkins M.E., Gur R.C., Horan W.P., Nuechterlein K.H., Seidman L.J., Stone W.S. The consortium on the genetics of schizophrenia: neurocognitive endophenotypes. Schizophr. Bull. 2007, 33(1):49-68.
31. Hall R.C. Global assessment of functioning. A modified scale. Psychosomatics 1995, 36(3):267-275.
32. Heinrichs R.W., Zakzanis K.K. Neurocognitive deficits in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998, 12(3):426-445.
33. Jones L.A., Cardno A.G., Sanders R.D., Owen M.J., Williams J. Sustained and selective attention as measures of genetic liability to schizophrenia. Schizophr. Res. 2001, 48(2-3):263-272.
34. Keefe R.S., Harvey P.D. Cognitive impairment in schizophrenia. Handb. Exp. Pharmacol. 2012, 213:11-37.
35. Kern R.S., Gold J.M., Dickinson D., Green M.F., Nuechterlein K.H., Baade L.E., Keefe R.S., Mesholam-Gately R.I., Seidman L.J., Lee C., Sugar C.A., Marder S.R. The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study. Schizophr. Res. 2011, 126(1-3):124-131.
36. Kraepelin E. Dementia Praecox and Paraphrenia 1919, E. & S Livingston, Edinburgh.
37. Laurent A., Saoud M., Bougerol T., d'Amato T., Anchisi A.M., Biloa-Tang M., Dalery J., Rochet T. Attentional deficits in patients with schizophrenia and in their non-psychotic first-degree relatives. Psychiatry Res. 1999, 89(3):147-159.
38. Lee J., Green M.F., Calkins M.E., Greenwood T.A., Gur R.E., Gur R.C., Lazzeroni L.C., Light G.A., Nuechterlein K.H., Radant A.D., Seidman L.J., Siever L.J., Silverman J.M., Sprock J., Stone W.S., Sugar C.A., Swerdlow N.R., Tsuang D.W., Tsuang M.T., Turetsky B.I., Braff D.L. Verbal working memory in schizophrenia: the moderating role of smoking status and antipsychotic medications. Schizophr. Res. 2015, 163(1-3):24-31. (in this issue).
39. Liu S.K., Chen W.J., Chang C.J., Lin H.N. Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: a trial of risperidone versus haloperidol. Neuropsychopharmacology 2000, 22(3):311-319.
40. Maier W., Franke P., Hain C., Kopp B., Rist F. Neuropsychological indicators of the vulnerability to schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 1992, 16(5):703-715.
41. Mausbach B.T., Harvey P.D., Goldman S.R., Jeste D.V., Patterson T.L. Development of a brief scale of everyday functioning in persons with serious mental illness. Schizophr. Bull. 2007, 33(6):1364-1372.
42. McCleery A., Addington J., Addington D. Substance misuse and cognitive functioning in early psychosis: a 2year follow-up. Schizophr. Res. 2006, 88(1-3):187-191.
43. Mirsky A.F., Lochhead S.J., Jones B.P., Kugelmass S., Walsh D., Kendler K.S. On familial factors in the attentional deficit in schizophrenia: a review and report of two new subject samples. J. Psychiatr. Res. 1992, 26(4):383-403.
44. Nestor P.G., Faux S.F., McCarley R.W., Sands S.F., Horvath T.B., Peterson A. Neuroleptics improve sustained attention in schizophrenia. A study using signal detection theory. Neuropsychopharmacology 1991, 4(2):145-149.
45. Nuechterlein K.H. Reaction time and attention in schizophrenia: a critical evaluation of the data and theories. Schizophr. Bull. 1977, 3(3):373-428.
46. Nuechterlein K.H. Signal detection in vigilance tasks and behavioral attributes among offspring of schizophrenic mothers and among hyperactive children. J. Abnorm. Psychol. 1983, 92(1):4-28.
47. Nuechterlein K.H. Vigilance in schizophrenia and related disorders. Handbook of Schizophrenia, Neuropsychology, Psychophysiology and Information Processing 1991, 397-433. Elsevier Science Publishers, Amsterdam. S.R. Steinhauer, J.H. Gruzelier, J. Zubin (Eds.).
48. Nuechterlein K.H., Asarnow R.F. Degraded Stimulus Continuous Performance Test (DS-CPT) Program for PCs, Windows Version 1.0 (8/4/06 Executable File) 2006, Authors, Los Angeles.
49. Nuechterlein K.H., Dawson M.E. Information processing and attentional functioning in the developmental course of schizophrenic disorders. Schizophr. Bull. 1984, 10(2):160-203.
50. Nuechterlein K.H., Parasuraman R., Jiang Q. Visual sustained attention: Image degradation produces rapid sensitivity decrement over time. Science 1983, 220(4594):327-329.
51. Nuechterlein K.H., Edell W.S., Norris M., Dawson M.E. Attentional vulnerability indicators, thought disorder, and negative symptoms. Schizophr. Bull. 1986, 12(3):408-426.
52. Nuechterlein K.H., Dawson M.E., Gitlin M., Ventura J., Goldstein M.J., Snyder K.S., Yee C.M., Mintz J. Developmental processes in schizophrenic disorders: longitudinal studies of vulnerability and stress. Schizophr. Bull. 1992, 18(3):387-425.
53. Nuechterlein K.H., Asarnow R.F., Subotnik K.L., Fogelson D.L., Ventura J., Torquato R.D., Dawson M.E. Neurocognitive vulnerability factors for schizophrenia: convergence across genetic risk studies and longitudinal trait/state studies. Origins and Development of Schizophrenia: Advances in Experimental Psychopathology 1998, 299-327. American Psychological Association, Washington, D.C. M.F. Lenzenweger, R.H. Dworkin (Eds.).
54. Nuechterlein K.H., Barch D.M., Gold J.M., Goldberg T.E., Green M.F., Heaton R.K. Identification of separable cognitive factors in schizophrenia. Schizophr. Res. 2004, 72(1):29-39.
55. Orzack M.H., Kornetsky C., Freeman H. The effects of daily administration of carphenazine on attention in the schizophrenic patient. Psychopharmacologia 1967, 11(1):31-38.
56. Rabin R.A., Zakzanis K.K., George T.P. The effects of cannabis use on neurocognition in schizophrenia: a meta-analysis. Schizophr. Res. 2011, 128(1-3):111-116.
57. Rapaport M.H., Bazzetta J., McAdams L.A., Patterson T., Jeste D.V. Validation of the scale of functioning in older outpatients with schizophrenia. Am. J. Geriatr. Psychiatry 1996, 4(3):218-228.
58. Rosvold H.E., Mirsky A.F., Sarason I., Bransome E.D., Beck L.H. A continuous performance test of brain damage. J. Consult. Psychol. 1956, 20(5):343-350.
59. Sabia S., Marmot M., Dufouil C., Singh-Manoux A. Smoking history and cognitive function in middle age from the Whitehall II study. Arch. Intern. Med. 2008, 168(11):1165-1173.
60. Saoud M., Saoud M., d'Amato T., Gutknecht C., Triboulet P., Bertaud J.P., Marie-Cardine M., Dalery J., Rochet T. Neuropsychological deficit in siblings discordant for schizophrenia. Schizophr. Bull. 2000, 26(4):893-902.
61. Seidman L.J., Breiter H.C., Goodman J.M., Goldstein J.M., Woodruff P.W., O'Craven K., Savoy R., Tsuang M.T., Rosen B.R. A functional magnetic resonance imaging study of auditory vigilance with low and high information processing demands. Neuropsychology 1998, 12(4):505-518.
62. Seidman L.J., Hellemann G., Nuechterlein K.H., Greenwood T.A., Braff D.L., Cadenhead K.S., Calkins M.E., Freedman R., Gur R.E., Gur R.C., Lazzeroni L.C., Light G.A., Olincy A., Radant A.D., Siever L.J., Silverman J.M., Sprock J., Stone W.S., Sugar C., Swerdlow N.R., Tsuang D.W., Tsuang M.T., Turetsky B.I., Green M.F. Factor structure and heritability of endophenotypes in schizophrenia: Findings from the Consortium on the Genetics of Schizophrenia (COGS-1). Schizophr. Res. 2015, 163(1-3):73-79. (in this issue).
63. Snitz B.E., MacDonald A.W., Carter C.S. Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. Schizophr. Bull. 2006, 32(1):179-194.
64. Swerdlow N.R., Gur R.E., Braff D.L. Consortium on the Genetics of Schizophrenia (COGS) assessment of endophenotypes for schizophrenia: an introduction to this special issue of schizophrenia research. Schizophr. Res. 2015, 163(1-3):9-16. (in this issue).
65. Thoma P., Daum I. Comorbid substance use disorder in schizophrenia: a selective overview of neurobiological and cognitive underpinnings. Psychiatry Clin. Neurosci. 2013, 67(6):367-383.
66. Wohlberg G.W., Kornetsky C. Sustained attention in remitted schizophrenics. Arch. Gen. Psychiatry 1973, 28(4):533-537.